StockpollyBeta
Get App
Delisting riskPopularity #4,794
CLDI · AMEX · Biotechnology

Calidi Biotherapeutics (CLDI)

Develops systemic oncolytic-virus platforms that deliver therapeutic payloads into tumors.

$1.09
vs last close−0.02 (−1.80%)

  1. Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

    GlobeNewsWire

  2. Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

    GlobeNewsWire

  3. Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

    GlobeNewsWire

  4. Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

    GlobeNewsWire

  5. Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

    Globe News Wire

  6. Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

    GlobeNewsWire

  7. Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    GlobeNewsWire

  8. Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit

    GlobeNewsWire

  9. Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study

    GlobeNewsWire

  10. Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026

    GlobeNewsWire

  11. Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting

    GlobeNewsWire

  12. Calidi Biotherapeutics Provides Required NYSE American Disclosure

    GlobeNewsWire

  13. Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

    GlobeNewsWire

  14. Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

    GlobeNewsWire

  15. Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI

    GlobeNewsWire

  16. Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

    GlobeNewsWire

  17. Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

    GlobeNewsWire

  18. Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing

    GlobeNewsWire

  19. Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

    GlobeNewsWire

  20. Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering

    GlobeNewsWire

  21. Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours — Here's Why

    Benzinga

  22. Calidi Biotherapeutics Announces Proposed Public Offering

    GlobeNewsWire

  23. Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

    GlobeNewsWire

  24. Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

    GlobeNewsWire